Truist lowered the firm’s price target on Lantheus to $110 from $125 but keeps a Buy rating on the shares after the firm’s discussion with key opinion leaders this week. The company has “many moving parts” with upcoming catalysts in the October-December timeframe and the stock could remain volatile, though at current levels, the risk-reward is upside-skewed, the analyst tells investors in a research note. Lantheus shares at their current $66 do not appropriately value the core + Pylarify + POINT assets, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LNTH:
- Truist med tech/biotech analysts hold analyst/industry conference call
- Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting
- Lantheus announces agreement to sell RELISTOR royalties to HealthCare Royalty
- Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty
- Lantheus adjusts FY23 adjusted EPS view to $5.60-$5.70 from $5.45-$5.70